Type A Monoamine Oxidase Catalyzes the Intraneuronal Deamination of Dopamine Within Nigrostriatal, Mesolimbic, Tuberoinfundibular and Tuberohypophyseal Neurons in the Rat

Overview

Journal J Neural Transm

Specialties Neurology
Physiology

Date 1981 Jan 1

PMID 6796650

Citations 6

Authors

K T Demarest

K E Moore

Affiliations

Soon will be listed here.

Abstract

Clorgyline (0.3-10 mg/kg, i.p.) inhibited type A monamine oxidase (5-hydroxytryptamine as substrate) but not type B monoamine oxidase (phenylethylamine as substrate) in homogenates of rat striatum and olfactory tubercle; deprenyl (0.3-3 mg/kg, i.p.) inhibited type B but not type A monoamine oxidase in these homogenates. The same doses of clorgyline increased concentrations of dopamine in striatum, and dopamine and norepinephrine in the olfactory tubercle, median eminence and posterior pituitary; they also reduced the concentrations of dihydroxyphenylacetic acid and the rate of synthesis of dopamine (DOPA accumulation after a decarboxylase inhibitor) in the same brain regions. On the other hand, the administration of deprenyl at doses that markedly inhibited type B monoamine oxidase did not alter the concentrations of dopamine, norepinephrine and dihydroxyphenylacetic acid or the rate of accumulation of DOPA in these brain regions. In addition, only clorgyline significantly lowered serum concentrations of prolactin. These results that type A monoamine oxidase catalyzes the intraneuronal deamination of dopamine within terminals of nigrostriatal, mesolimbic, tuberoinfundibular and tuberohypophyseal dopamine neurons.

Citing Articles

The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.

Goldstein D Int J Mol Sci. 2021; 22(11).

PMID: 34206133 PMC: 8199574. DOI: 10.3390/ijms22115999.

The catecholaldehyde hypothesis: where MAO fits in.

Goldstein D J Neural Transm (Vienna). 2019; 127(2):169-177.

PMID: 31807952 PMC: 10680281. DOI: 10.1007/s00702-019-02106-9.

Regional differences in the effect of pargyline on dopamine concentrations in the rat hypophysis.

Holzbauer M, Racke K, Mann S, Cooper T, Cohen G, Krause U J Neural Transm. 1984; 59(2):91-104.

PMID: 6726218 DOI: 10.1007/BF01255408.

Inhibition of rat brain monoamine oxidase type A by 2-aminotetralin and tetrahydroisoquinoline analogues of dopamine.

Feenstra M, van der Velden T, Dijkstra D, Hommes O, Horn A Pharm Weekbl Sci. 1983; 5(4):131-3.

PMID: 6622205 DOI: 10.1007/BF01961468.

Effect of a reversible and selective MAO-A inhibitor (cimoxatone) on diurnal variation in plasma prolactin level in man.

Strolin Benedetti M, Eschalier A, Lesage A, Dordain G, Rovei V, Zarifian E Eur J Clin Pharmacol. 1984; 26(1):71-7.

PMID: 6538844 DOI: 10.1007/BF00546712.

References

Yang H, Neff N . The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther. 1974; 189(3):733-40. View

Demarest K, Moore K . Accumulation of L-dopa in the median eminence: an index of tuberoinfundibular dopaminergic nerve activity. Endocrinology. 1980; 106(2):463-8. DOI: 10.1210/endo-106-2-463. View

Yang H, Neff N . Beta-phenylethylamine: a specific substrate for type B monoamine oxidase of brain. J Pharmacol Exp Ther. 1973; 187(2):365-71. View

Coquil J, Goridis C, Mack G, Neff N . Monoamine oxidase in rat arteries: evidence for different forms and selective localization. Br J Pharmacol. 1973; 48(4):590-9. PMC: 1776159. DOI: 10.1111/j.1476-5381.1973.tb08245.x. View

Jarrott B, Iversen L . Noradrenaline metabolizing enzymes in normal and sympathetically denervated vas deferens. J Neurochem. 1971; 18(1):1-6. DOI: 10.1111/j.1471-4159.1971.tb00161.x. View

Johnston J . Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol. 1968; 17(7):1285-97. DOI: 10.1016/0006-2952(68)90066-x. View

Horn A, Cuello A, Miller R . Dopamine in the mesolimbic system of the rat brain: endogenous levels and the effects of drugs on the uptake mechanism and stimulation of adenylate cyclase activity. J Neurochem. 1974; 22(2):265-70. DOI: 10.1111/j.1471-4159.1974.tb11589.x. View

Knoll J, Magyar K . Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol. 1972; 5:393-408. View

Bjorklund A, Moore R, Nobin A, Stenevi U . The organization of tubero-hypophyseal and reticulo-infundibular catecholamine neuron systems in the rat brain. Brain Res. 1973; 51:171-91. DOI: 10.1016/0006-8993(73)90371-5. View

10.

Umezu K, Moore K . Effects of drugs on regional brain concentrations of dopamine and dihydroxyphenylacetic acid. J Pharmacol Exp Ther. 1979; 208(1):49-56. View

11.

Chen H, Simpkins J, Mueller G, Meites J . Effects of pargyline on hypothalamic biogenic amines and serum prolactin. LH and TSH in male rats. Life Sci. 1977; 21(4):533-41. DOI: 10.1016/0024-3205(77)90093-5. View

12.

Demarest K, Moore K . Comparison of dopamine synthesis regulation in the terminals of nigrostriatal, mesolimbic, tuberoinfundibular and tuberohypophyseal neurons. J Neural Transm. 1979; 46(4):263-77. DOI: 10.1007/BF01259333. View

13.

Goridis C, Neff N . Monoamine oxidase in sympathetic nerves: a transmitter specific enzyme type. Br J Pharmacol. 1971; 43(4):814-8. PMC: 1665724. DOI: 10.1111/j.1476-5381.1971.tb07217.x. View

14.

Demarest K, Smith D, Azzaro A . The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons. J Pharmacol Exp Ther. 1980; 215(2):461-8. View

15.

Waldmeier P, Delini-Stula A, Maitre L . Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1976; 292(1):9-14. DOI: 10.1007/BF00506483. View

16.

Hall D, Logan B, Parsons G . Further studies on the inhibition of monoamine oxidase by M and B 9302 (clorgyline). I. Substrate specificity in various mammalian species. Biochem Pharmacol. 1969; 18(6):1447-54. DOI: 10.1016/0006-2952(69)90258-5. View

17.

Moore R, Bloom F . Central catecholamine neuron systems: anatomy and physiology of the dopamine systems. Annu Rev Neurosci. 1978; 1:129-69. DOI: 10.1146/annurev.ne.01.030178.001021. View

18.

Atack C, Magnusson T . Individual elution of noradrenaline (together with adrenaline), dopamine, 5-hydroxytryptamine and histamine from a single, strong cation exchange column, by means of mineral acid-organic solvent mixtures. J Pharm Pharmacol. 1970; 22(8):625-7. DOI: 10.1111/j.2042-7158.1970.tb10584.x. View

19.

MacLeod R, Login I . Control of prolactin secretion by the hypothalamic catecholamines. Adv Sex Horm Res. 1976; 2:211-31. View

20.

Carlsson A, KEHR W, Lindqvist M, Magnusson T, Atack C . Regulation of monoamine metabolism in the central nervous system. Pharmacol Rev. 1972; 24(2):371-84. View